CYP19A1 and breast cancer: Since estrogen biosynthesis is regulatedby aromatase (CYP19A1), and aldosterone biosynthesis is modulatedby aldosterone synthase (CYP11B2), a dual inhibitor would allow thetreatment of BC while reducing the cardiovascular risks typical ofthese patients.